MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Movement Disorders Associated with Infectious Encephalitis in Pediatric Patients

    M. Mnif, H. Benrhouma, T. Benyounes, H. Klaa, Z. Miladi, A. Zioudi, I. Turki, I. Kraoua (Tunis, Tunisia)

    Objective: The objective of our study is to report the clinical and imaging profile of a cohort of pediatric patients with movement disorders (MDs) associated…
  • 2024 International Congress

    Diagnostic challenges with novel SCA variants: A case of STUB1 mutation

    D. Vijaywargiya, A. Frank, T. Chabrashvili (Liverpool, USA)

    Objective: We present a case of SCA48 found on multi-gene sequencing panel [MGSP] after negative dementia workup. Background: Spinocerebellar ataxia [SCA] is a genotypically &…
  • 2024 International Congress

    Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model

    A. Centner, N. Lipari, C. Budrow, G. Mcmanus, I. Sandoval, K. Tseng, F. Manfredsson, C. Bishop (Binghamton, USA)

    Objective: Levodopa (LD) is the standard treatment for Parkinson’s Disease (PD) despite risk of LD-induced dyskinesia (LID) development within a decade of treatment. Serotonergic (5-HT)…
  • 2024 International Congress

    Recrudescence of a Compensated Hemidystonia-hemiatrophy Syndrome After COVID-19 Infection

    A. Kundrick, H. Fernandez (Cleveland, USA)

    Objective: To educate readers about a unique presentation of hemidystonia-hemiatrophy syndrome which presented after an infection with COVID-19 Background: Hemidystonia-hemiatrophy syndrome is a rare disorder…
  • 2024 International Congress

    Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss

    S. Jha (Kolkata, India)

    Objective: To describe a case of proven Hashimoto Encephalopathy presenting with oromandibular dystonia (OMD) and orofacial dyskinesias (OFD) Background: Neurologic manifestations of Hashimoto’s Encephalopathy (HE)…
  • 2024 International Congress

    A Rare Case of Hemicorea Secondary to Giant Perivascular Space: A Case Report

    M. Merscher, C. Lobo, V. de Souza, R. Souza, R. Helmer, L. Pinho, L. Urzeda, W. Machado-Filho, T. Ganho, W. Avelar (Campinas, Brazil)

    Objective: To describe a rare cause of unilateral chorea caused by a structural lesion with few descriptions in literature. Background: While chorea typically manifests in…
  • 2024 International Congress

    Chorea after MRgFUS for the treatment of essential tremor: A case report

    A. Ferreirós, AN. Martínez, M. Peralta, J. Bejarano, A. Sánchez-Gómez, F. Valldeoriola, JO. Rumià (Barcelona, Spain)

    Objective: To describe a case of chorea after magnetic resonance guided focused ultrasound (MRgFUS) for the treatment of essential tremor (ET). Background: ET can provide…
  • 2024 International Congress

    Cryptococcal meningitis as a rare cause of acute generalized chorea: a report of an interesting case

    C. Wantaneeyawong, C. Teekaput, K. Thiankhaw (Chiang Mai, Thailand)

    Objective: To describe a case with cryptococcal meningitis as a rare cause of adult-onset acute generalized chorea. Background: Chorea is an abnormal movement characterized as…
  • 2024 International Congress

    Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease

    L. Ponsati, S. Hansen, M. Scharff, H. Klitgaard, S. Kauppinen, E. Bezard, J. Erler (København SV, Denmark)

    Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…
  • 2024 International Congress

    Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease

    XD. Yang, Q. Xiao, XQ. He (Shanghai, China)

    Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 335
  • 336
  • 337
  • 338
  • 339
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley